ArticleJournal of ovarian research2026
CBX2 promotes cisplatin resistance in ovarian cancer via SIAH2-mediated β-catenin stabilization and ATG9B-dependent autophagy activation.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPlatinum-based chemotherapy is the first-line therapeutic strategy for ovarian cancer (OC), and resistance to it adversely affects most OC patients. CBX2 plays an essential role in cancer progression and is widely thought to be involved in cisplatin (DDP) resistance. This study aimed to investigate the molecular mechanism of CBX2 in DDP resistance in OC. MATERIALS AND
methodsThe human normal ovarian epithelial cell line (IOSE80) and OC cell lines (SK-OV-3 and OVcar3) were used. The functions of CBX2 and ATG9B were explored by transfecting overexpression and silencing plasmids into OC cells. Drug-resistant DDP OC cell lines were established. Real-time quantitative PCR (qPCR), Western blotting, and immunofluorescence (IF) analysis were conducted to evaluate the molecular expression at the mRNA and protein levels. The Cell Counting Kit-8 (CCK-8) assay measured the IC
resultsCBX2 was highly expressed in OC and was associated with DDP resistance. Besides, CBX2 overexpression enhanced DDP resistance and autophagy in OC cells. As expected, CBX2 silencing suppressed autophagy and DDP resistance in OC cells. Mechanistically, CBX2 stabilized β-catenin by inhibiting ubiquitin-mediated degradation. Inhibiting the Wnt/β-catenin pathway suppressed CBX2-induced autophagy and decreased DDP resistance in OC cells. Activating the Wnt/β-catenin pathway promoted CBX2-induced autophagy and increased DDP resistance in OC cells. ATG9B mediated CBX2-induced autophagy and DDP resistance. Finally, ATG9B inhibition rescued the effects of CBX2-mediated autophagy and DDP resistance.
conclusionCBX2 promotes cisplatin resistance in OC via SIAH2-mediated β-catenin stabilization and ATG9B-dependent autophagy activation. Overall, our study reveals a hitherto undocumented role of CBX2 in mediating DDP resistance, providing insights for potential therapeutic biomarkers to overcome DDP resistance in OC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.